Enveric Biosciences, Inc.
NasdaqCM ENVB
Enveric Biosciences, Inc. Price to Book Ratio (P/B) on February 05, 2025
Enveric Biosciences, Inc. Price to Book Ratio (P/B) is NA on February 05, 2025, a NA change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.
-
Enveric Biosciences, Inc. 52-week high Price to Book Ratio (P/B) is NA on February 05, 2025, which is NA below the current Price to Book Ratio (P/B).
-
Enveric Biosciences, Inc. 52-week low Price to Book Ratio (P/B) is NA on February 05, 2025, which is NA below the current Price to Book Ratio (P/B).
-
Enveric Biosciences, Inc. average Price to Book Ratio (P/B) for the last 52 weeks is NA.
Key data
| Date | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield | Price to Earnings Ratio (P/E) |
|---|
Market news
Loading...
Don’t Miss A Beat
NasdaqCM: ENVB
| CEO | Dr. Joseph Edward Tucker Ph.D. |
| IPO Date | May 4, 2015 |
| Location | United States |
| Headquarters | 4851 Tamiami Trail North |
| Employees | 7 |
| Sector | Healthcare |
| Industries | |
Description
Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
Key trends
Past 5 years
Similar companies
Zura Bio Limited
USD 1.78
4.09%
StockViz Staff
February 6, 2025
Any question? Send us an email